DHT-U:CA:TSX-DRI Healthcare Trust (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

CAD 8.26

Change

0.00 (0.00)%

Market Cap

CAD 0.54B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
BHC:CA Bausch Health Companies Inc

-0.07 (-0.62%)

CAD 3.94B
TLRY:CA Tilray Inc

-0.06 (-2.87%)

CAD 1.89B
CURA:CA Curaleaf Holdings Inc.

N/A

CAD 1.61B
CRON:CA Cronos Group Inc

-0.10 (-3.34%)

CAD 1.07B
DHT-UN:CA DRI Healthcare Trust

+0.08 (+0.69%)

CAD 0.75B
WEED:CA Canopy Growth Corp

-0.05 (-1.18%)

CAD 0.60B
AOV:CA Amotiv Limited

+0.05 (+0.93%)

CAD 0.58B
GUD:CA Knight Therapeutics Inc.

+0.05 (+0.93%)

CAD 0.58B
CPH:CA Cipher Pharmaceuticals Inc

+0.21 (+1.46%)

CAD 0.38B
ACB:CA Aurora Cannabis Inc

-0.14 (-2.06%)

CAD 0.36B

ETFs Containing DHT-U:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -14.05% 38% F 9% A-
Dividend Return 2.65% 100% F 36% F
Total Return -11.39% 38% F 9% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 15.19% 77% C+ 80% B-
Dividend Return 19.52% 82% B 83% B
Total Return 4.33% 100% F 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 39.11% 59% D- 22% F
Risk Adjusted Return 49.91% 91% A- 62% D
Market Capitalization 0.54B 65% D 60% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.